Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities between November 7, 2023, and June 26, 2024, due to significant stock price decline following FDA approval updates [1][5]. Company Overview - Elanco Animal Health develops products for pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [2]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [3]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q3 2024 with a launch in Q4 2024 [3]. - On June 27, 2024, Elanco indicated that Zenrelia would include a boxed safety warning, potentially slowing product adoption by approximately 25%, with expected FDA approval in Q3 2024 and a commercial launch in Q4 2024 for both products [4]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [5].

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Elanco Animal Health Incorporated regarding a class action lawsuit due to alleged misleading statements and omissions related to product safety and approval timelines [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 7, 2023, to June 26, 2024 [2]. - Allegations include that Elanco misrepresented the safety of Zenrelia, a canine dermatology product, and was unlikely to meet its own timeline for U.S. approval and launch of Zenrelia and Credelio Quattro [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by December 6, 2024, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Lawsuit Overview - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Elanco securities [2] - The case is pending in the U S District Court of Maryland under the caption Barpar v Elanco Animal Health Incorporated et al No 24-cv-02912 [2] Allegations Against Elanco - The complaint alleges that Elanco develops products to treat diseases in animals with two key treatments Zenrelia and Credelio Quattro currently under FDA review [3] - Elanco initially stated that the FDA had all necessary data to complete its review and expected approval before the end of June 2024 [4] - On June 27 2024 Elanco announced that the FDA would not approve either drug in June 2024 and Zenrelia would come with a boxed warning on safety [4] Impact on Stock Price - Following the announcement Elanco's stock price declined over 21 from $17 97 per share on June 26 2024 to $14 27 per share on June 27 2024 [5] Legal Investigation - BFA Law is investigating whether Elanco and certain executives made materially false and/or misleading statements to investors regarding the FDA's approval of its drugs [5] Legal Options for Investors - Investors who suffered losses in Elanco Animal Health Incorporated NYSE ELAN may have legal options and are encouraged to submit their information to BFA Law [6] - Representation is on a contingency fee basis with no cost to shareholders who are not responsible for any court costs or expenses of litigation [6] About Bleichmar Fonti & Auld LLP - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation [7] - The firm was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been recognized as Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters [7] - BFA has achieved notable successes including recovering over $900 million from Tesla Inc's Board of Directors and $420 million from Teva Pharmaceutical Ind Ltd [7]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - A federal lawsuit has been filed against Elanco Animal Health Inc. and certain executives for allegedly making false and misleading statements regarding the safety and market prospects of their product Zenrelia between November 7, 2023, and June 26, 2024 [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is defined as November 7, 2023, to June 26, 2024, with a lead plaintiff deadline set for December 6, 2024 [2]. - The complaint claims that Elanco downplayed safety risks associated with Zenrelia, an oral Janus kinase inhibitor, while overstating its potential for a quick U.S. market launch [2]. Group 2: Product Controversy - The controversy began on June 26, 2024, when Elanco announced that Zenrelia's label would include a boxed warning due to safety issues identified during trials with unvaccinated dogs, which is expected to significantly impede product adoption and limit treatment days [3]. - Following this announcement, Elanco's stock fell by over 20% [4]. Group 3: Company Response - During the Q2 earnings call on August 4, 2024, CEO Jeffrey N. Simmons acknowledged that the new label language would "slow the initial product adoption curve" and projected a 25% reduction in treatment days due to limitations related to vaccine usage as outlined in the boxed warning [4].

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=110017&fro ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-h ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=109662 ...